中国·金沙娱场城(31399·China认证)官方网站-Best Platform

Company Profile

——

Guangzhou Sinogen Pharmaceutical Co., Ltd. is a biotechnology company committed to the development and production of innovative biological oncology drugs to meet the global demand for the treatment of a broad malignant tumors.

Since its establishment in 2016, under the leadership of Dr. Allan Zhao and other three nationally distinguished experts, and through the joint efforts of dozens of researchers, the company has gradually established the world's first rapid broad-spectrum oncolytic bacteria technology platform, and completed the preclinical study, the development of CMC manufacturing process, and the construction of GMP-compliant large-scale production facilities of the core product, an oncolytic bacteria, named as SalMet-Vec     . Our first-in-class product SalMet-Vec    has obtained the IND approvals from US FDA , Taiwan FDA and China NMPA, and has launched international multi-center phase I/IIa clinical trials for a variety of malignant solid tumors in the United States, Taiwan region and mainland China.

Honor

——

Milestones

——

Chairman's Speech

——

Thank you for visiting us! Sinogen is entering a new era of prosperous development!
In 2017, China's official announcement to join the International Council for Harmonisation (ICH) has enabled the country to rapidly transit from a generic drugs-dominated industry over the past decades to a new era aimed at developing global innovative medicines. Sinogen will seize such a rare opportunity and rise to the challenge with full confidence.
Sinogen was founded in 2016 by four nationally distinguished experts returning from the United States. They are biomedical experts with an international perspective and rich experiences in drug research and development, manufacturing quality control, regulatory affairs, and clinical trials. Since its establishment, the company has always persistently advocated for the spirit of innovation, committed itself to the research and development of innovative medicine with global intellectual property rights, and set the goal of breakthrough progress in the treatment of many difficult-to-treat cancers.
We have always promoted the concept of people-oriented working environment, continuous innovation, integrity, cooperation and sharing, and aspiring to be the leading pharmaceutical enterprise in China. We always look for and welcome ambitious people sharing our development philosophy to join hands with us in creating a brilliant future of Sinogen!

®

®